In patients with severe central nervous system (CNS) diseases, life-threatening hyponatremia results from two main causes: the syndromes of inappropriate secretion of antidiuretic hormone (SIADH) and cerebral salt wasting (CSW). Clinical manifestations of the two conditions may be similar but their pathogeneses are fundamentally diverse. Distinguishing SIADH from CSW is based on the differential diagnoses of dilutional hyponatremia due to an excessive amount of water in the body (SIADH) and depletional hyponatremia caused by extensive natriuresis (CSW).
Inadequate, otherwise inexplicable loss of sodium and chloride ions into the urine was first described in 1950 by Peters and colleagues in patients with organic CNS involvement 1 . Currently, the condition is referred to as a cerebral salt wasting syndrome (CSW) described in patients with brain tumours, traumas, intracranial haemorrhage, ischemic strokes and CNS infections 2, 3, 4 . Although its pathophysiology is not completely understood, increased natriuretic peptides from damaged nerve tissues and decreased sympathoadrenal kidney innervation are assumed 5 . Both mechanisms lead to severe hyponatremia, hypoosmolality and extracellular fluid volume depletion. The diagnosis is based on excluding other causes of increased natriuresis, such as e.g. mineralocorticoid deficiency or administration of diuretics 6 . The differential diagnostics of CSW versus syndrome of inappropriate secretion of antidiuretic hormone (SIADH) rests upon distinguishing between hyponatremic hyperhydration -and thus an excess of clear water -(SIADH) and hyponatremic dehydration (CSW) 7, 8 . Unlike SIADH management requiring strict fluid restriction and diuretic therapy, the treatment of CSW aims at achieving an adequate fluid balance and substitution of hyponatremia 9 . In some observational studies CSW has been found more frequently than SIADH. Most of the reports we have found in the literature come from neuroanaesthesia and neurocritical care units, but there is little evidence about its prevalence in non-critical neurology patients 9 .
We report the case of a 48-year-old, previously healthy male with a recent history of a behaviour disorder who was admitted to a psychiatric department. A CT scan of the brain verified a tumour sized 20*23*10 mm affecting the area of the basal ganglia and the right part of the thalamus and oppressing the third brain ventricle. CT-guided stereotactic biopsy of the tumor (Fig. 1) of the site and contrast magnetic resonance imaging (Fig. 2) were indicated. Histologic examination of the brain tissue biopsy revealed a diffuse infiltration with middle to large sized lymphocytes (immunophenotype CD 20+, bcl-2+, Ki-67+ in > 80% cells, CD 10−). The diagnosis of primary diffuse large B-cell lymphoma of the brain was established. Further staging evaluation showed no generalized disease. After admission to the Department of Hemato-oncology, the patient was soporous (Glasgow coma scale 7) and laboratory tests revealed severe serum hyponatremia (113 mmol/l, normal range 130-144 mmol/l), hypochloremia (81 mmol/l, normal 95-110 mmol/l), serum hypoosmolality (244 mmol/kg, normal 275-300 mmol/kg) and marked polyuria (9600 ml/day), with normal serum levels of urea, creatinine, glucose and calcium. Urinalysis showed high specific gravity of the urine (1035 kg/m 3 ) and extreme wasting of Na + (1116 mmol/day, normal were increased (631 ug/l, normal 1-93 ug/l), with no apparent previous history of cardiac disease. The patient was intensively hydrated in an effort to achieve balanced volumes and ions. Chemotherapy was initiated with highdose methotrexate according to DeAngelis protocol 10 . After the first chemotherapy cycle, the CT scan confirmed regression of the tumour site to about one third of its original size. This was also accompanied by patient's improved cognition (Glasgow coma scale 14) as well as decreased polyuria and urine electrolyte excretion. Eventually, it was concluded that the diagnosis was cerebral salt wasting syndrome.
In patients with severe CNS disorders, disturbances of sodium metabolism are frequent. Distinction made between SIADH and CSW is of crucial importance for selecting adequate treatment strategy. The association between lymphomas involving deep structures of the brain and CSW that has not been described to date. The prevalence of the syndrome in hemato-oncological patients may be higher than commonly believed. Thus, it is necessary to investigate the causes of hyponatremia in patients with CNS lymphomas since early diagnosis and adjustment of the internal environment are a condition for subsequent intensive chemotherapy. 
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